1. Home
  2. BNR vs CIF Comparison

BNR vs CIF Comparison

Compare BNR & CIF Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

Logo Burning Rock Biotech Limited

BNR

Burning Rock Biotech Limited

HOLD

Current Price

$19.75

Market Cap

233.7M

Sector

Health Care

ML Signal

HOLD

Logo MFS Intermediate High Income Fund

CIF

MFS Intermediate High Income Fund

HOLD

Current Price

$1.72

Market Cap

31.1M

Sector

Finance

ML Signal

HOLD

Company Overview

Basic Information
Metric
BNR
CIF
Founded
2014
1988
Country
China
United States
Employees
N/A
N/A
Industry
Medical Specialities
Trusts Except Educational Religious and Charitable
Sector
Health Care
Finance
Exchange
Nasdaq
Nasdaq
Market Cap
233.7M
31.1M
IPO Year
2020
N/A

Fundamental Metrics

Financial Performance
Metric
BNR
CIF
Price
$19.75
$1.72
Analyst Decision
Analyst Count
0
0
Target Price
N/A
N/A
AVG Volume (30 Days)
73.4K
43.9K
Earning Date
11-20-2025
01-01-0001
Dividend Yield
N/A
10.11%
EPS Growth
N/A
N/A
EPS
N/A
N/A
Revenue
$75,749,382.00
N/A
Revenue This Year
$136.32
N/A
Revenue Next Year
N/A
N/A
P/E Ratio
N/A
N/A
Revenue Growth
5.56
N/A
52 Week Low
$2.18
$1.47
52 Week High
$23.59
$1.77

Technical Indicators

Market Signals
Indicator
BNR
CIF
Relative Strength Index (RSI) 61.06 49.20
Support Level $15.71 $1.68
Resistance Level $18.42 $1.76
Average True Range (ATR) 2.16 0.02
MACD -0.17 -0.00
Stochastic Oscillator 63.65 33.33

Price Performance

Historical Comparison
BNR
CIF

About BNR Burning Rock Biotech Limited

Burning Rock Biotech Ltd is a cancer diagnostics company. It is a NGS-based cancer therapy selection company. Its cancer therapy selection platform is built upon advanced proprietary technologies, comprehensive portfolio of products and a two-pronged market-driven commercial infrastructure addressing both larger hospitals through company's in-hospital model and smaller hospitals through its central laboratory model. It had three operating segments, including Central laboratory business, In-hospital business and Pharma research and development services. It generates the majority of its revenue from Central laboratory business. Its products are Pan-HEME, OncoScreen-WES, brPROPHET, OncoScreen Plus, and others.

About CIF MFS Intermediate High Income Fund

Mfs Intermediate High Income Fund is a United States based diversified closed-end management investment company. Its investment objective is to seek high current income but may also consider capital appreciation. The fund invests a majority of its net assets, including borrowings for investment purposes, in high-income debt instruments. Its portfolio of investments includes investment grade corporate bonds, government securities and other securities.

Share on Social Networks: